Endo Health Solutions — Opioid Marketing Practices
Endo Resolves Criminal and Civil Investigations Tied to Opana ER Marketing
Source: U.S. Department of Justice
TL;DR: Endo Resolves Criminal and Civil Investigations Tied to Opana ER Marketing This case resulted in a Bankruptcy Resolution resolution and demonstrates the impact of whistleblower protections in recovering funds from fraud.
Summary
Endo Health Solutions Inc. (in bankruptcy) agreed to a global resolution covering criminal and civil investigations tied to the sales and marketing of Opana ER. DOJ stated that, as part of the proposed criminal resolution, Endo would plead guilty to a misdemeanor FDCA charge involving misbranding based on marketing claims about Opana ER's purported abuse-deterrent or tamper/crush-resistant qualities without supporting clinical data. DOJ also announced a civil False Claims Act settlement intended to address alleged losses to federal healthcare programs that paid for Opana ER, along with a related bankruptcy settlement framework for resolving the government's monetary claims.
Our Take
Opioid marketing FCA matters tend to turn on what the field force was actually told to do—and what compliance concerns were surfaced (and then handled) inside the company. The strongest internal proof is usually operational: call notes and targeting lists, sales training materials, speaker program and consulting records, and compliance escalations showing that risk flags were understood but not acted on. If you recognize a pattern where marketing strategy is built around "outlier" prescribers or where claims about product attributes outpace the data, focus on the decision trail: who approved the message, how it was reinforced, and what internal checks were bypassed.
Read the full article from the original source:
View Original ArticleOpens in a new tab. Content from U.S. Department of Justice.
Notice
The summaries above are based on publicly available information released by the U.S. Department of Justice and are provided for informational purposes only. They do not constitute legal advice, investigative findings, or allegations by Disclosure Strategy. Our commentary reflects general, experience-based observations about how False Claims Act matters commonly arise and is not a statement about any party's liability.